Project Grant R41DK142247
Award Date 9/15/25
Completion Date 9/14/26
Dollars Obligated $310K
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $687,416 Project Grant under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) to Lynntech Inc., a small business technology development company based in College Station, Texas. The grant will support the development of a cutaneous gel to deliver a therapeutic with an intriguing mechanism of action to effectively treat diabetic foot ulcers (DFUs). The project aims to: (1) prepare,...
- This federal Project Grant award of $1,024,812 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop novel treatments for diabetic foot ulcers (DFU). The award supports research conducted by Epoulosis Therapeutics Inc. to leverage single-cell RNA sequencing data and in vivo studies to repurpose the drug metrifonate for enhancing wound healing in DFU...
- This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program will fund the development of an advanced wound care product to treat diabetic foot ulcers. The $305,000 award to Therapeutic Bandage Products, Inc. will support the creation of a patented microneedle bandage that delivers three therapeutic agents to disinfect the wound, prevent bacterial biofilm formation, and attract white blood cells to aid healing. This...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotech company in Virginia. The grant supports the development of novel, oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes (T2D). The specific aims are to: 1) Evaluate the therapeutic efficacy of the lead drug candidate...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $268,377 to The University of North Texas Health Science Center at Fort Worth (UNTHSC) to develop and evaluate a novel device for accelerating the healing of diabetic foot ulcers (DFUs) using high-frequency, low-amplitude vibration (HFLAV). The key objectives are to: 1) enhance...
- This Project Grant award of $348,150.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports the development of Avantamine, a novel antimicrobial chloramine formulation, by Halomine Inc. (doing business as Avantguard). The goal is to optimize Avantamine's efficacy against bacteria found in diabetic foot ulcers to improve treatment and healing outcomes. The project involves evaluating...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Gelsana Therapeutics Inc. a $649,984 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop Provasliex Gel, a zwitterionic hydrogel that delivers controlled release of platelet-derived growth factor (PDGF). The goal is to improve wound healing for diabetic foot ulcers by reducing inflammation, promoting vascularization, and accelerating the wound...
- The Project Grant award of $324,793 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant was awarded to Nucb1 Holdings LLC on September 1, 2025 with an expected completion date of August 31, 2026. The purpose of the grant is to develop a platform technology for discovering conformation-specific, anti-protofibril monoclonal antibodies (mAbs) that target...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a component of the National Institutes of Health, awarded a $350,000 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Microvascular Tissues, Inc. The grant supports the evaluation of a microvascular tissue graft treatment in rat models of diabetic peripheral neuropathy. The project aims to assess the ability of this novel microvascular tissue graft to improve...
- This $1,021,719.00 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Emmyon, Inc., is developing a novel small molecule therapeutic (EMMY1-25) that has demonstrated the ability to promote weight loss without muscle loss and protect against dysfunction of pancreatic beta cells in mouse models of obesity and type 2...